A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer-Reference-Cited by-同舟云学术

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

Published:2004-10-15 Issue:20 Volume:10 Page:6764-6769
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Lebowitz Peter F.,Eng-Wong Jennifer,Swain Sandra M.,Berman Arlene,Merino Maria J.,Chow Catherine K.,Venzon David,Zia Farah,Danforth David,Liu Edison,Zujewski JoAnne

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi‐Stimuli Nanocomposite Therapeutic: Docetaxel Targeted Delivery and Synergies in Treatment of Human Breast Cancer Tumor;Small;2020-09-18

2. Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival;SpringerPlus;2015-01-13

3. Locally Advanced Breast Cancer (LABC);Surgical Oncology;2014-09-20

4. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy;Breast Cancer Research and Treatment;2013-10-12

5. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer;Cancer Chemotherapy and Pharmacology;2013-02-03